Antibody–drug conjugates in solid tumors: current landscape, challenges, and future directions
The emergence of bispecific ADC, immune-stimulating ADC platforms, and next-generation payload designs are now driving the evolution of ADC technology toward broader patient applicability and improved safety profiles, which hold the potential to translate into new therapeutic opportunities for patients with high-incide...